| Closing Price ($) | Shares Out (MM) | Market Cap ($MM) |
| $0.00 | 0 | $0 |
| 20-F | 2018-12-31 | Annual: 2018-12-31 |
| 20-F | 2017-12-31 | Annual: 2017-12-31 |
| 20-F | 2016-12-31 | Annual: 2016-12-31 |
| Comps ($'000 TTM) | Market Cap | Assets | Liabilities | Revenue | Gross Profit | Net Income | EBITDA | EV |
|---|---|---|---|---|---|---|---|---|
| Advaxis (ADXS) | 5,775 | 56,133 | 6,864 | 22,012 | 0 | 1,812 | 3,429 | -35,980 |
| Tonix Pharmaceuticals Holding (TNXP) | 8,683 | 15,008 | 2,186 | 0 | 0 | -23,639 | -23,595 | -3,567 |
| Delmar Pharmaceuticals (DMPI) | 3,296 | 4,037 | 2,070 | 0 | 0 | 8,048 | 8,048 | -423 |
| Diffusion Pharmaceuticals (DFFN) | 1,924 | 18,929 | 2,752 | 0 | 0 | -17,534 | -17,962 | -6,448 |
| Phibro Animal Health (PAHC) | 1,272 | 726,671 | 510,656 | 624,112 | 264,624 | 54,713 | 109,193 | 174,989 |
| OHR Pharmaceutical (OHRP) | 10,129 | 8,693 | 752 | 0 | 0 | -9,529 | -8,750 | 8,704 |
| Therapix Biosciences (TRPX) | 0 | 4,560 | 0 | 0 | 0 | 0 | -1,518 | |
| Grifols (GRFS) | 12,477,046 | 7,780,442 | 0 | 0 | 0 | 0 | -592,178 | |
| Novo Nordisk (NVO) | ||||||||
| Bioblast Pharma (ORPN) | 39,270 | 11,034 | 1,328 | 0 | 0 | -3,073 | -3,073 | 29,534 |
| Trillium Therapeutics (TRIL) | 55,459 | 13,858 | 0 | 0 | 0 | 0 | -0 | |
| Kiniksa Pharmaceuticals (KNSA) | 308,137 | 32,940 | 0 | 0 | -169,998 | -170,154 | -287,447 | |
| AstraZeneca (AZN) | 60,651,000 | 46,607,000 | 0 | 0 | 0 | 0 | -893,000 | |
| Immtech Pharmaceuticals (IMMP) | ||||||||
| Zomedica Pharmaceuticals (ZOM) | 9,479 | 1,797 | 0 | 0 | -24,413 | -24,124 | -5,822 | |
| VTV Therapeutics (VTVT) | 9,072 | 21,914 | 10,646 | 0 | -6,924 | -4,119 | 5,935 | |
| Nabriva Therapeutics (NBRV) | 678,758 | 83,645 | 40,240 | 3,486 | 0 | -125,573 | -123,455 | 629,164 |
| Affimed (AFMD) | 116,174 | 0 | 0 | 0 | 0 | -0 | ||
| Zealand Pharma (ZEAL) | ||||||||
| Intec Pharma (NTEC) | 46,860 | 11,751 | 0 | 0 | -20,665 | -20,593 | -20,796 |
| Balance Sheet ($'000) | 2017-12-31 | 2018-12-31 |
| Cash | 9,219 | 1,518 |
| Accounts Receivable | ||
| Inventory | ||
| PP&E | ||
| Assets | 9,566 | 4,560 |
| Accounts Payable | ||
| Long-Term Debt | ||
| Liabilities | ||
| Stockholders' Equity | ||
| Income Statement ($'000) | 2017-12-31 | 2018-12-31 |
| Revenue | ||
| Cost of Revenue | ||
| Gross Profit | ||
| R&D | ||
| SG&A | ||
| Tax | ||
| Net Income | ||
| Cash Flow ($'000) | 2017-12-31 | 2018-12-31 |
| Cash Operating | ||
| Cash Investing | ||
| Cash Financing |